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Abstract
T-wave   oversensing   can   cause   inappropriate   implantable   cardioverter-defibrillator   (ICD) 
therapies that are difficult to correct. Remote monitoring allows follow-up of ICD patients 
without visiting the hospital and can help in early detection of any malfunctions. We describe the 
case of a patient who experienced inappropriate antitachycardia pacing therapy due to T-wave 
oversensing; the problem was promptly detected by remote monitoring and corrected by device 
reprogramming.
Introduction
Inappropriate shocks are an important disadvantage of implantable cardioverter-defibrillators 
(ICD) [1]. Following supraventricular arrhythmias, inappropriate device sensing is the most 
common cause of inappropriate shocks [2]. Remote monitoring has lessened the workload 
entailed in ICD follow-up and is helpful for early detection of malfunctions. We describe a case 
of inappropriate ICD therapy caused by T-wave oversensing not due to lead malfunction neither 
clinical causes that was promptly detected by remote monitoring, which allowed rapid correction 
of the problem by device reprogramming.                                                                         
Case   Report                                                                            
A 43-year-old man with chronic ischemic heart disease, ejection fraction of 22%, in NYHA 
functional class II, and with a narrow QRS, was referred to our department for implantation of an 
ICD in primary prevention. A single-chamber device (Virtuoso VR, Medtronic, Minneapolis, 
Minnesota, USA) with an active-fixation lead (Sprint Quattro Secure™ 6947, Medtronic, 
Minneapolis, Minnesota, USA) was implanted in the right ventricular apex. At the time of 
implantation, ventricular sensing with a stable intrinsic amplitude of 9 mV without T-wave 
sensing was achieved. A single zone of detection-therapy at 188 bpm was programmed, with 
antitachycardia pacing (ATP) during charging and shock at 35 J, as well as a sensitivity 
threshold of 0.3 mV. All functional and lead integrity parameters were normal before hospital 
discharge and at an in-clinic follow-up visit 1 month later. Subsequent follow-up was performed 
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by remote monitoring (CareLink, Medtronic, Minnesota, Minneapolis, USA). The automatic 
notification alarms were enabled; these alarms were sent to our e-mail address whenever the 
system detected impedances outside the programmed range, ventricular intervals less than 130 
ms (Lead Integrity Alert™ algorithm, Medtronic, Minneapolis, Minnesota, USA), a battery 
voltage indicating elective replacement, or antitachycardia therapy.                                        
Two   months   post-implant,   we   received   a   therapy   alert   that   reported   7   episodes   of 
tachyarrhythmia in the programmed area (Figure 1); 4 were classified as nonsustained and 3 as 
sustained. All episodes were treated according to the programmed parameters with ATP during 
charging (Figure 2), which was not noticed by the patient. A review of stored electrograms 
showed that the episodes were wrongly classified as ventricular fibrillation and were actually T-
wave oversensing during normal sinus rhythm (Figure 3). After ATP, no shocks were delivered 
because T-wave oversensing disappeared during redetection. The patient was notified to come 
for an in-clinic check-up. No abnormal data related to device operation or lead integrity were 
observed, and the patient reported no symptoms that suggested myocardial ischemia or heart 
failure, neither electrolytic alterations nor long QT interval. The device was reprogrammed by 
increasing the sensitivity threshold to 0.6 mV. No other events were observed 12 months after 
follow-up.
Figure 1: Detailed view of episodes recorded on the patient transmission website. It shows the seven episodes, heart 
rate   sensed,   therapy   applied   and   success.                                                                
Figure 2: Detection and therapy diagram shown in a graph of intervals between ventricular sensing events. After 
normal sensed sinus rhythm, the device begins to sense events in ventricular fibrillation zone in a sustained-episode 
fashion, so it applies therapy (ATP) that finishes the episode.                                                                                   
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Figure 3: Bipolar (top) and unipolar (middle) intracardiac electrograms and marker channel and intervals (ms) for 
one of the events. Note the intermittent nature of T-wave sensing and how it disappears after ATP therapy during 
charging,   thereby   inhibiting   the   shock.                                                                  
Discussion
The ICD has clearly proven its efficacy in the prevention of sudden death secondary to ventricular 
arrhythmia in high-risk patients. However, up to 15% of patients experience inappropriate shocks 
during the first year [1]. In 20%, the shocks are secondary to inadequate device sensing [2]. T-
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wave sensing is the most common cause of ventricular oversensing and representing 14% of such 
cases [3]. Although the cause was not identified in all patients, Brugada syndrome, long QT 
syndrome, and hypertrophic cardiomyopathy have been implicated in some cases. Reversible 
causes are water-electrolyte imbalances and acute myocardial ischemia, and their correction is the 
first step to attempt to solve the problem. Nevertheless, high T-wave sensing counts are usually 
hard to resolve and believed to be related to a technical failure in device sensing [4]. In most 
published cases, it was necessary to reposition the implanted lead, insert an additional lead for 
sensing, apart from the high power circuit, or implant a new generator. Noninvasive resolution 
through device reprogramming, as in our patient (who required a simple adjustment in the 
sensitivity threshold), is unusual.                                                                             
The number of ICD implants has risen recently due to the results of new studies, but has also 
increased the health care burden in terms of follow-up. ICD remote monitoring has proven to be 
extremely useful in routine patient follow-up, as it allows device malfunctions and arrhythmic 
events to be detected early through web-based alarms [5]. However, to our knowledge, there have 
been no previous reports of ICD malfunction due to T-wave oversensing with inappropriate 
therapy not perceived by the patient (ATP), in which the malfunction was promptly detected and 
corrected thanks to remote monitoring. The web-alert we recived informing  us about an 
antitachycardia therapy, allowed us to analyze the episode and notify the patient to come for 
prompt device reprogramming, a measure that successfully corrected the problem and prevented 
new episodes that could have led to inappropriate shocks.                                   
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